MedTrace Logo

PAI-1 Levels and Predicting Covid-19 Patients' Prognosis

NCT04997928 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-08-10

No results posted yet for this study

Summary

The primary aim of our study is to understand the effects of Covid-19 disease on vascular inflammation and coagulation cascade, and secondarily, to investigate its utility in predicting disease prognosis by analyzing serum PAI-1 levels in patients with different severity. The study is planned as a prospective, cross-sectional study that will include patients admitted to Covid-19 services between January 18, 2021, and August 30, 2021. A total of 80 volunteers will be enrolled in the trial whose age, gender, and BMI are planned to be matched.The study will be conducted on four groups. Group 1 (n=20; with mild symptoms), Group 2 (n=20; with moderate symptoms), Group 3 (n=20; with severe symptoms) and Group 4 (n=20; Control group).

All participants who accepted the study will have their sociodemographic data, medical history, and vital signs (respiratory rate, saturation, temperature, and blood pressure values) recorded at the start of the study. The pulmonologist in the study will also classify the patient group's chest X-ray and chest tomography findings and the thymus gland dimensions. After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

Conditions

  • Covid-19 Positivity Confirmed With PCR Positivity in the Nasopharyngeal Swab
  • Symptomatic Covid -19 Positive Patients Who Require Hospitalization
  • Patients Who Did Not Vaccinate Against Covid-19
  • Patients Among 20 to 90 Years of Age
  • Healthy Control Patients of the Same Age

Interventions

OTHER

Serum PAI-1 alpha analysis.

After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Ozgür Kartal, MD · University of Health Sciences Turkey, Gulhane Research and Training Hospital

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2021-08-30
Completion
2021-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997928 on ClinicalTrials.gov